BÜHLMANN fCAL® ELISA RUO Applications Citations Archives - Page 2 of 2 - Buhlmann Diagnostics Corp

Category: BÜHLMANN fCAL® ELISA RUO Applications Citations

All of the publications in this citation list describe applications that are outside of product claims (Intended use is: The BÜHLMANN fCAL® ELISA aids in the diagnosis of inflammatory bowel disease (IBD), specifically Crohn’s disease (CD) and ulcerative colitis (UC) and aids in the differentiation of IBD from irritable bowel syndrome (IBS) in conjunction with other laboratory and clinical findings.) thus the “non-diagnosis” citations below should be used for information only.

Validation of a Care Pathway for the Use of Faecal Calprotectin in Monitoring Patients with Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation: Turvill J, Rook L, Rawle M, et al. Validation of a care pathway for the use of faecal calprotectin in monitoring patients with Crohn's disease. Frontline Gastroenterology Published Online First: 30 January 2017. doi: 10.1136/flgastro-2016-100780. Highlights from this Publication “In patients with Crohn’s Disease, established on therapy, fecal calprotectin effectively identifies those who
Continue Reading

Fecal Calprotectin in Healthy Children Aged 1-4 Years

BÜHLMANN fCAL® ELISA Citation: Zhu, Q,Feng Li, Junli Wang, Lixiao Shen, Xiaoyang Sheng. Fecal Calprotectin in Healthy Children Aged 1-4 Years, PLOS ONE. 2016. http://dx.doi.org/10.1371/journal.pone.0150725.

Highlight from this Publication:

“Children aged from 1 to 4 years old have lower FC concentrations compared with healthy infants (<1years), and higher FC concentrations when comparing with children older than 4 years and adults.”
Continue Reading

Comparison of Three Tests for Faecal Calprotectin in Children and Young Adults: a Retrospective Monocentric Study

BÜHLMANN fCAL® ELISA Citation: Prell, C, Nagel D, Freudenberg H, Schwarzer A, Koletzko S. Comparison of three tests for faecal calprotectin in children and young adults: a retrospective monocentric study, BMJ Open. 2014;4:e004558 doi:10.1136/bmjopen-2013-004558.

Highlights from this Publication

“In conclusion, measurement of FC in paediatric patients with unspecific symptoms is very helpful in order to avoid invasive procedure.”
Continue Reading

Fecal Calprotectin in Inflammatory Bowel Disease

BÜHLMANN fCAL® ELISA Citation Walsham and Sherwood. Fecal calprotectin in inflammatory bowel disease, Clinical and Experimental Gastroenterology. 2016; 9: 21–29.Published online 2016 Jan 28. doi: 10.2147/CEG.S51902

Highlight from this Publication

“The choice of a cutoff will depend on whether sensitivity or specificity is considered to be the most important and needs to be made taking into consideration the clinical features of an individual patient.”
Continue Reading

Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis

BÜHLMANN fCAL® ELISA Citation Theede, K. ,Holck S, Ibsen P, Kallemose T, Nordgaard-Lassen I, Nielsen AM. Fecal Calprotectin Predicts Relapse and Histological Mucosal Healing in Ulcerative Colitis, Inflamm Bowel Dis. 2016 May;22(5):1042-8. doi: 10.1097/MIB.0000000000000736. Highlights from this Publication “…our histological inflammatory activity score is closely related to the concentration of FC and thereby has the advantage
Continue Reading

Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery

BÜHLMANN fCAL® ELISA Citation Wright, E. K., , Kamm MA, De Cruz P, Hamilton AL et. al. Measurement of Fecal Calprotectin Improves Monitoring and Detection of Recurrence of Crohn’s Disease After Surgery, Gastroenterology 2015 May;148(5):938-947.e1. doi: 10.1053/j.gastro.2015.01.026. Highlights from this Publication “The present study has shown that FC concentration is sufficiently sensitive to monitor for recurrence of
Continue Reading

Prospective Evaluation of the Predictive Value of Faecal Calprotectin in Quiescent Crohn’s Disease

BÜHLMANN fCAL® ELISA Citation Naismith, Smith LA, Barry SJ, Munro JI, Laird S, Rankin K, Morris AJ, Winter JW, Gaya DR. A prospective evaluation of the predictive value of faecal calprotectin in quiescent Crohn’s disease. J Crohns Colitis. 2014 Sep;8(9):1022-9. doi: 10.1016/j.crohns.2014.01.029. Highlights from this Publication “The FC result, obtained by non-invasive means, can provide prognostic information
Continue Reading

Fecal Calprotectin is Equally Sensitive in Crohn’s Disease Affecting the Small Bowel and Colon

BÜHLMANN fCAL® ELISA Citation: Jensen, M.D., Kjeldsen J, Nathan T. Fecal calprotectin is equally sensitive in Crohn’s disease affecting the small bowel and colon. Scand J Gastroenterol. 2011 Jun;46(6):694-700. doi: 10.3109/00365521.2011.560680.

Highlights from this Publication:

“The first study to show that fecal calprotectin is equally sensitive in colonic and small bowel CD.”
Continue Reading

Value Fecal Calprotectin in the Evaluation of Patients with Abdominal Discomfort: An Observational Study

BÜHLMANN fCAL® ELISA Citation Manz, M,  Burri E, Rothen C, Tchanguizi N, Niederberger C, Rossi L, Beglinger C, Lehmann FS. Value of fecal calprotectin in the evaluation of patients with abdominal discomfort: an observational study. BMC Gastroenterol. 2012 Jan 10;12:5. doi: 10.1186/1471-230X-12-5. Highlights from this Publication “All together, those results support the concept that fecal calprotectin is
Continue Reading

Monoclonal antibody testing for fecal calprotectin is superior to Polyclonal Testing of Fecal Calprotectin and Lactoferrin to Identify Organic Intestinal Disease in Patients with Adominal Discomfort

BÜHLMANN fCAL® ELISA Citation Burri E, Manz M., Rothen C, Rossi L,Beglinger C, Lehmann S. Monoclonal antibody testing for fecal calprotectin is superior to polyclonal testing of fecal calprotectin and lactoferrin to identify organic intestinal disease in patients with abdominal discomfort. Clinica Chimica Acta. 2013 Feb; 416: 41-47.  doi: 10.1016/j.cca.2012.11.008 Highlights from this Publication “…we demonstrated, that the
Continue Reading